BioVie (BIVI)

• Market cap: $15.5M
• 1 day: 6.00%
• 5 days: 13.39%
• 1 month: -23.56%
• 3 months: -62.46%
• 6 months: -24.93%
• Year to date: -61.43%
• 1 year: -82.15%
• 5 years: -99.16%
• 10 years: -99.16%
• Sector: Healthcare
• Industry: Biotechnology

About: BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Employees: 14

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

677% more capital invested

Capital invested by funds: $195K [Q3] → $1.52M (+$1.32M) [Q4]

400% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 4

80% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 5

59% more funds holding

Funds holding: 27 [Q3] → 43 (+16) [Q4]

2.14% more ownership

Funds ownership: 2.12% [Q3] → 4.26% (+2.14%) [Q4]

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $14K